Caricamento...
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
OBJECTIVES: To review published cost-effectiveness analyses (CEA) assessing bortezomib (BTZ) for multiple myeloma (MM) and explore possible bias affecting the cost-effectiveness of BTZ. METHODS: Literature was searched for published CEAs assessing BTZ or BTZ-containing regimens for MM from 2003 to 2...
Salvato in:
| Pubblicato in: | Clinicoecon Outcomes Res |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861606/ https://ncbi.nlm.nih.gov/pubmed/27217786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S104195 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|